Skip to main content
SpringerLink
Log in

Onconephrology

  • Chapter
  • First Online:
Approaches to Chronic Kidney Disease

  • 1194 Accesses

Abstract

As cancer survival has improved over the years, more cancer patients will experience side effects of treatment and survive long enough to develop conditions like chronic kidney disease. Kidney function is considered in the choice and dosing of chemotherapeutic drugs, and development of chronic kidney disease (CKD) and acute kidney injury can complicate medication and patient management. Development of acute kidney injury (AKI) is common during the clinical course of cancer patients and can be due to cancer-nonspecific causes like volume depletion and cancer-related causes like in multiple myeloma or can be therapy-related. The pathophysiology behind therapy-related AKI has broadened with the advent of targeted and immune-mediated cancer therapy. For patients who eventually progress to end-stage renal disease (ESRD), the discussion of pursuing renal replacement therapy is complex as both cancer and ESRD have their own impact on mortality and quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cancer of Any Site — Cancer Stat Facts. https://seer.cancer.gov/statfacts/html/all.html. Accessed 24 Aug 2020.

  2. CKD Evaluation and Management – KDIGO. https://kdigo.org/guidelines/ckd-evaluation-and-management/. Accessed 24 Aug 2020.

  3. Casal MA, Nolin TD, Beumer JH. Estimation of kidney function in oncology implications for anticancer drug selection and dosing. Clin J Am Soc Nephrol. 2019;14(4):587–95. https://doi.org/10.2215/CJN.11721018.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Cohen EP, Krzesinski JM, Launay-Vacher V, Sprangers B. Onco-nephrology: core curriculum 2015. Am J Kidney Dis. 2015;66(5):869–83. https://doi.org/10.1053/j.ajkd.2015.04.042.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Janowitz T, Williams EH, Marshall A, et al. New model for estimating glomerular filtration rate in patients with cancer. J Clin Oncol. 2017;35(24):2798–805. https://doi.org/10.1200/JCO.2017.72.7578.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Mulaomerović A, Halilbašić A, Čičkušić E, Zavašnik-Bergant T, Begić L, Kos J. Cystatin C as a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma. Cancer Lett. 2007;248(2):192–7. https://doi.org/10.1016/j.canlet.2006.07.004.

    Article  CAS  PubMed  Google Scholar 

  7. Schardijn GHC, Statius Van Eps LW. β 2 -microglobulin: its significance in the evaluation of renal function. Kidney Int. 1987;32(5):635–41. https://doi.org/10.1038/ki.1987.255.

    Article  CAS  PubMed  Google Scholar 

  8. Christiansen CF, Johansen MB, Langeberg WJ, Fryzek JP, Sørensen HT. Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study. Eur J Intern Med. 2011;22(4):399–406. https://doi.org/10.1016/j.ejim.2011.05.005.

    Article  PubMed  Google Scholar 

  9. Salahudeen AK, Doshi SM, Pawar T, Nowshad G, Lahoti A, Shah P. Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center. Clin J Am Soc Nephrol. 2013;8(3):347–54. https://doi.org/10.2215/CJN.03530412.

    Article  PubMed  Google Scholar 

  10. Lahoti A, Nates JL, Wakefield CD, Price KJ, Salahudeen AK. Costs and outcomes of acute kidney injury in critically ill patients with cancer. J Support Oncol. 2011;9(4):149–55. https://doi.org/10.1016/j.suponc.2011.03.008.

    Article  PubMed  Google Scholar 

  11. Libório AB, Abreu KLS, Silva GB, et al. Predicting hospital mortality in critically ill cancer patients according to acute kidney injury severity. Oncology. 2011;80(3-4):160–6. https://doi.org/10.1159/000329042.

    Article  PubMed  Google Scholar 

  12. Soares M, Salluh JIF, Carvalho MS, Darmon M, Rocco JR, Spector N. Prognosis of critically ill patients with cancer and acute renal dysfunction. J Clin Oncol. 2006;24(24):4003–10. https://doi.org/10.1200/JCO.2006.05.7869.

    Article  PubMed  Google Scholar 

  13. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26(16):2767–78. https://doi.org/10.1200/JCO.2007.15.0177.

    Article  CAS  PubMed  Google Scholar 

  14. Perry Wilson F, Berns JS. Onco-nephrology: tumor lysis syndrome. Clin J Am Soc Nephrol. 2012;7(10):1730–9. https://doi.org/10.2215/CJN.03150312.

    Article  CAS  PubMed  Google Scholar 

  15. Cairo MS, Coiffier B, Reiter A, Younes A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010;149(4):578–86. https://doi.org/10.1111/j.1365-2141.2010.08143.x.

    Article  CAS  PubMed  Google Scholar 

  16. Belay Y, Yirdaw K, Enawgaw B. Tumor lysis syndrome in patients with hematological malignancies. J Oncol. 2017; https://doi.org/10.1155/2017/9684909.

  17. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844–54. https://doi.org/10.1056/NEJMra0904569.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Jones GL, Will A, Jackson GH, Webb NJA, Rule S, on Behalf of the British Committee for Standards in Haematology. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol. 2015;169(5):661–71. https://doi.org/10.1111/bjh.13403.

    Article  PubMed  Google Scholar 

  19. Darmon M, Guichard I, Vincent F, Schlemmer B, Azoulay L. Prognostic significance of acute renal injury in acute tumor lysis syndrome. Leuk Lymphoma. 2010;51(2):221–7. https://doi.org/10.3109/10428190903456959.

    Article  PubMed  Google Scholar 

  20. Małyszko J, Kozłowska K, Kozłowski L, Małyszko J. Nephrotoxicity of anticancer treatment. Nephrol Dial Transplant. 2017;32(6):924–36. https://doi.org/10.1093/ndt/gfw338.

    Article  CAS  PubMed  Google Scholar 

  21. Latcha S, Jaimes EA, Patil S, Glezerman IG, Mehta S, Flombaum CD. Long-term renal outcomes after cisplatin treatment. Clin J Am Soc Nephrol. 2016;11(7):1173–9. https://doi.org/10.2215/CJN.08070715.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol. 1996;14(7):2101–12. https://doi.org/10.1200/JCO.1996.14.7.2101.

    Article  CAS  PubMed  Google Scholar 

  23. Siegert W, Beyer J, Strohscheer I, et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. J Clin Oncol. 1994;12(6):1223–31. https://doi.org/10.1200/JCO.1994.12.6.1223.

    Article  CAS  PubMed  Google Scholar 

  24. Reece PA, Stafford I, Russell J, Khan M, Gill PG. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol. 1987;5(2):304–9. https://doi.org/10.1200/JCO.1987.5.2.304.

    Article  CAS  PubMed  Google Scholar 

  25. Widemann BC, Balis FM, Kempf-Bielack B, et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma: incidence, treatment, and outcome. Cancer. 2004;100(10):2222–32. https://doi.org/10.1002/cncr.20255.

    Article  CAS  PubMed  Google Scholar 

  26. Perazella MA. Onco-nephrology: renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol. 2012;7(10):1713–21. https://doi.org/10.2215/CJN.02780312.

    Article  CAS  PubMed  Google Scholar 

  27. Howard SC, McCormick J, Pui C, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471–82. https://doi.org/10.1634/theoncologist.2015-0164.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Widemann BC, Schwartz S, Jayaprakash N, et al. Efficacy of glucarpidase (carboxypeptidase G2) in patients with acute kidney injury after high-dose methotrexate therapy. Pharmacotherapy. 2014;34(5):427–39. https://doi.org/10.1002/phar.1360.

    Article  CAS  PubMed  Google Scholar 

  29. Widemann BC, Balis FM, Murphy RF, et al. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. J Clin Oncol. 1997;15(5):2125–34. https://doi.org/10.1200/JCO.1997.15.5.2125.

    Article  CAS  PubMed  Google Scholar 

  30. Stavroulopoulos A, Nakopoulou L, Xydakis AM, Aresti V, Nikolakopoulou A, Klouvas G. Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed. Ren Fail. 2010;32(8):1000–4. https://doi.org/10.3109/0886022X.2010.501930.

    Article  CAS  PubMed  Google Scholar 

  31. Glezerman IG, Pietanza MC, Miller V, Seshan SV. Kidney tubular toxicity of maintenance pemetrexed therapy. Am J Kidney Dis. 2011;58(5):817–20. https://doi.org/10.1053/j.ajkd.2011.04.030.

    Article  CAS  PubMed  Google Scholar 

  32. Michels J, Spano JP, Brocheriou I, Deray G, Khayat D, Izzedine H. Acute tubular necrosis and interstitial nephritis during pemetrexed therapy. Case Rep Oncol. 2009;2(1):53–6. https://doi.org/10.1159/000208377.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Glezerman IG, Jaimes EA. Chemotherapy and kidney injury. Am Soc Nephrol. 2016:1–10. https://www.asn-online.org/education/distancelearning/curricula/onco/Chapter11.pdf

  34. Schallreuter KU, Gleason FK, Wood JM. The mechanism of action of the nitrosourea anti-tumor drugs on thioredoxin reductase, glutathione reductase and ribonucleotide reductase. Biochim Biophys Acta. 1990;1054(1):14–20. https://doi.org/10.1016/0167-4889(90)90199-N.

    Article  CAS  PubMed  Google Scholar 

  35. Morris A, Warenius HM, Tobin M. Forced diuresis to reduce nephrotoxicity of streptozotocin in the treatment of advanced metastatic insulinoma. Br Med J (Clin Res Ed). 1987;294(6580):1128. https://doi.org/10.1136/bmj.294.6580.1128.

    Article  Google Scholar 

  36. Blake-Haskins JA, Lechleider RJ, Kreitman RJ. Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res. 2011;17(18):5858–66. https://doi.org/10.1158/1078-0432.CCR-11-0804.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Humphreys BD, Sharman JP, Henderson JM, et al. Gemcitabine-associated thrombotic microangiopathy. Cancer. 2004;100(12):2664–70. https://doi.org/10.1002/cncr.20290.

    Article  PubMed  Google Scholar 

  38. Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W, Vigil J. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer. 1999;85(9):2023–32. https://doi.org/10.1002/(SICI)1097-0142(19990501)85:9<2023::AID-CNCR21>3.0.CO;2-2.

    Article  CAS  PubMed  Google Scholar 

  39. Izzedine H, Isnard-Bagnis C, Launay-Vacher V, et al. Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant. 2006;21(11):3038–45. https://doi.org/10.1093/ndt/gfl507.

    Article  CAS  PubMed  Google Scholar 

  40. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358(11):1129–36. https://doi.org/10.1056/NEJMoa0707330.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Nussbaum EZ, Perazella MA. Update on the nephrotoxicity of novel anticancer agents. Clin Nephrol. 2018;89(3):149–65. https://doi.org/10.5414/CN109371.

    Article  CAS  PubMed  Google Scholar 

  42. Halimi J-M, Azizi M, Bobrie G, et al. Author’s personal copy vascular and renal effects of anti-angiogenic therapy Author’s personal copy. https://doi.org/10.1016/j.nephro.2008.10.002.

  43. Capasso A, Benigni A, Capitanio U, et al. Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. Kidney Int. 2019;96(3):555–67. https://doi.org/10.1016/j.kint.2019.04.043.

    Article  PubMed  Google Scholar 

  44. Izzedine H, Escudier B, Lhomme C, et al. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center. Med (United States). 2014;93(24):333–9. https://doi.org/10.1097/MD.0000000000000207.

    Article  CAS  Google Scholar 

  45. Salahudeen AK, Bonventre JV. Onconephrology: the latest frontier in the war against kidney disease. J Am Soc Nephrol. 2013;24(1):26–30. https://doi.org/10.1681/ASN.2012070690.

    Article  PubMed  Google Scholar 

  46. Brosnan EM, Weickhardt AJ, Lu X, et al. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib. Cancer. 2014;120(5):664–74. https://doi.org/10.1002/cncr.28478.

    Article  CAS  PubMed  Google Scholar 

  47. Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018;8(MAR) https://doi.org/10.3389/fonc.2018.00086.

  48. Gupta S, Cortazar FB, Riella LV, Leaf DE. Immune checkpoint inhibitor nephrotoxicity: update 2020. Kidney360. 2020;1(2):130–40. https://doi.org/10.34067/kid.0000852019.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Seethapathy H, Zhao S, Chute DF, et al. The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol. 2019;14(12):1692–700. https://doi.org/10.2215/CJN.00990119.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Cortazar FB, Kibbelaar ZA, Glezerman IG, et al. Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol. 2020;31(2):435–46. https://doi.org/10.1681/ASN.2019070676.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Thompson JA. New NCCN guidelines: recognition and management of immunotherapy-related toxicity. J Natl Compr Canc Netw. 2018;16:594–6. Harborside Press. https://doi.org/10.6004/jnccn.2018.0047.

    Article  PubMed  Google Scholar 

  52. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714–68. https://doi.org/10.1200/JCO.2017.77.6385.

    Article  CAS  PubMed  Google Scholar 

  53. Venkatachalam K, Malone AF, Heady B, Santos RD, Alhamad T. Poor outcomes with the use of checkpoint inhibitors in kidney transplant recipients. Transplantation. 2020;104(5):1041–7. https://doi.org/10.1097/TP.0000000000002914.

    Article  PubMed  Google Scholar 

  54. Jhaveri KD, Rosner MH. Chimeric antigen receptor T cell therapy and the kidney: what the nephrologist needs to know. Clin J Am Soc Nephrol. 2018;13(5):796–8. https://doi.org/10.2215/CJN.12871117.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321–30. https://doi.org/10.1182/blood-2016-04-703751.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Cohen EP, Robbins MEC. Radiation nephropathy. Semin Nephrol. 2003;23(5):486–99. https://doi.org/10.1016/S0270-9295(03)00093-7.

    Article  PubMed  Google Scholar 

  57. Cohen EP, Pais P, Moulder JE. Chronic kidney disease after hematopoietic stem cell transplantation. Semin Nephrol. 2010;30(6):627–34. https://doi.org/10.1016/j.semnephrol.2010.09.010.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Hingorani S. Renal complications of hematopoietic-cell transplantation. N Engl J Med. 2016;374(23):2256–67. https://doi.org/10.1056/NEJMra1404711.

    Article  PubMed  Google Scholar 

  59. Satwani P, Bavishi S, Jin Z, et al. Risk factors associated with kidney injury and the impact of kidney injury on overall survival in pediatric recipients following allogeneic stem cell transplant. Biol Blood Marrow Transplant. 2011;17(10):1472–80. https://doi.org/10.1016/j.bbmt.2011.02.006.

    Article  PubMed  Google Scholar 

  60. Flores FX, Brophy PD, Symons JM, et al. Continuous renal replacement therapy (CRRT) after stem cell transplantation. A report from the prospective pediatric CRRT Registry Group. Pediatr Nephrol. 2008;23(4):625–30. https://doi.org/10.1007/s00467-007-0672-2.

    Article  PubMed  Google Scholar 

  61. Cohen EP, Piering WF, Kabler-Babbitt C, Moulder JE. End-stage renal disease (ESRD) after bone marrow transplantation: poor survival compared to other causes of ESRD. Nephron. 1998;79(4):408–12. https://doi.org/10.1159/000045085.

    Article  CAS  PubMed  Google Scholar 

  62. Leung N, Bridoux F, Batuman V, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol. 2019;15(1):45–59. https://doi.org/10.1038/s41581-018-0077-4.

    Article  PubMed  Google Scholar 

  63. Nasr SH, Valeri AM, Sethi S, et al. Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies. Am J Kidney Dis. 2012;59(6):786–94. https://doi.org/10.1053/j.ajkd.2011.12.028.

    Article  PubMed  Google Scholar 

  64. Sethi S, Rajkumar SV, D’Agati VD. The complexity and heterogeneity of monoclonal immunoglobulin–associated renal diseases. J Am Soc Nephrol. 2018;29(7):1810–23. https://doi.org/10.1681/ASN.2017121319.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046–60. https://doi.org/10.1056/NEJMra1011442.

    Article  CAS  PubMed  Google Scholar 

  66. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21–33. https://doi.org/10.4065/78.1.21.

    Article  PubMed  Google Scholar 

  67. Winearls CG. Acute myeloma kidney. Kidney Int. 1995;48:1347–61. Nature Publishing Group. https://doi.org/10.1038/ki.1995.421.

    Article  CAS  PubMed  Google Scholar 

  68. Sathick IJ, Drosou ME, Leung N. Myeloma light chain cast nephropathy, a review. J Nephrol. 2019;32(2):189–98. https://doi.org/10.1007/s40620-018-0492-4.

    Article  PubMed  Google Scholar 

  69. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48. https://doi.org/10.1016/S1470-2045(14)70442-5.

    Article  PubMed  Google Scholar 

  70. Hutchison CA, Batuman V, Behrens J, et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol. 2012;8(1):43–51. https://doi.org/10.1038/nrneph.2011.168.

    Article  CAS  Google Scholar 

  71. Richmond J, Sherman RS, Diamond HD, Craver LF. Renal lesions associated with malignant lymphomas. Am J Med. 1962;32(2):184–207. https://doi.org/10.1016/0002-9343(62)90289-9.

    Article  CAS  PubMed  Google Scholar 

  72. Lefaucheur C, Stengel B, Nochy D, et al. Membranous nephropathy and cancer: epidemiologic evidence and determinants of high-risk cancer association. Kidney Int. 2006;70(8):1510–7. https://doi.org/10.1038/sj.ki.5001790.

    Article  CAS  PubMed  Google Scholar 

  73. Lien YHH, Lai LW. Pathogenesis, diagnosis and management of paraneoplastic glomerulonephritis. Nat Rev Nephrol. 2011;7(2):85–95. https://doi.org/10.1038/nrneph.2010.171.

    Article  CAS  PubMed  Google Scholar 

  74. Ishioka J, Kageyama Y, Inoue M, Higashi Y, Kihara K. Prognostic model for predicting survival after palliative urinary diversion for ureteral obstruction: analysis of 140 cases. J Urol. 2008;180(2):618–21. https://doi.org/10.1016/j.juro.2008.04.011.

    Article  PubMed  Google Scholar 

  75. Wong L-M, Cleeve LK, Milner AD, Pitman AG. Malignant ureteral obstruction: outcomes after intervention. Have things changed? J Urol. 2007;178(1):178–83. https://doi.org/10.1016/j.juro.2007.03.026.

    Article  PubMed  Google Scholar 

  76. Furrer MA, Spycher SCJ, Büttiker SM, et al. Comparison of the diagnostic performance of contrast-enhanced ultrasound with that of contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging in the evaluation of renal masses: a systematic review and meta-analysis. Eur Urol Oncol. 2019; https://doi.org/10.1016/j.euo.2019.08.013.

  77. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol. 2003;170(6 I):2217–20. https://doi.org/10.1097/01.ju.0000095475.12515.5e.

    Article  PubMed  Google Scholar 

  78. Yanik EL, Clarke CA, Snyder JJ, Pfeiffer RM, Engels EA. Variation in cancer incidence among patients with esrd during kidney function and nonfunction intervals. J Am Soc Nephrol. 2016;27(5):1495–504. https://doi.org/10.1681/ASN.2015040373.

    Article  CAS  PubMed  Google Scholar 

  79. Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet. 1999;354(9173):93–9. https://doi.org/10.1016/S0140-6736(99)06154-1.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medicine-Nephrology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA

    Maria P. Martinez Cantarin

  2. Medicine-Nephrology, Johns Hopkins University, Baltimore, MD, USA

    Christina Mejia

Authors
  1. Maria P. Martinez Cantarin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christina Mejia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria P. Martinez Cantarin .

Editor information

Editors and Affiliations

  1. Thomas Jefferson University, Philadelphia, PA, USA

    Jerry McCauley

  2. Department of Medicine, Division of Nephrology, Sidney Kimmel School of Medicine, Thomas Jefferson University, Philadelphia, PA, USA

    Seyed Mehrdad Hamrahian

  3. Division of Nephrology, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA

    Omar H. Maarouf

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Martinez Cantarin, M.P., Mejia, C. (2022). Onconephrology. In: McCauley, J., Hamrahian, S.M., Maarouf, O.H. (eds) Approaches to Chronic Kidney Disease . Springer, Cham. https://doi.org/10.1007/978-3-030-83082-3_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-83082-3_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-83081-6

  • Online ISBN: 978-3-030-83082-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation